Sanofi (ENXTPA:SAN) Stock Looks Cheap On Earnings Yet Fairly Valued Overall

Sanofi’s share price has inched higher by 7.5% over the past five years, a modest return that sits alongside a high value score and a recent stream of product and R&D updates. This raises the question of whether the stock quietly leans cheap or is fairly priced for its current prospects.

• A 7.5% return over five years suggests Sanofi has delivered only a small gain for long term holders, so any valuation upside today may matter more for investors looking ahead.
• Regulatory progress around treatments such as subcutaneous Sarclisa Escena and Nexviazyme can support expectations for future cash flows, while execution risk across Sanofi’s broader pipeline and product portfolio may still weigh on how much value the market is willing to ascribe.
• Sanofi screens as undervalued across the broader checks, with the company passing 6 of 6 valuation tests according to the value score, which implies the current pricing leans on the inexpensive side rather than richly valued.

The issue now is whether Sanofi’s current share price offers enough of a discount to compensate for its mixed past returns and the risks around how its pipeline and key products translate into long term value.

Find out why Sanofi's -3.1% return over the last year is lagging behind its peers.

Is Sanofi a Bargain on Earnings?

The P/E ratio is often a straightforward way to compare how the market prices Sanofi against other large pharmaceutical stocks, using current earnings as a common yardstick. Sanofi trades on about 18.9x earnings, slightly below both the wider pharmaceuticals industry average of 20.9x and the peer group average of 19.2x. On this simple comparison, that suggests a modest discount.

On a more tailored view, the fair P/E ratio for Sanofi is estimated at 36.4x, a level that reflects the company’s earnings profile, risk mix and sector context rather than just raw averages. This is considerably higher than the current 18.9x. Despite recent headlines around approvals such as Sarclisa Escena and progress with Nexviazyme, the stock is not priced at a premium to its peers on earnings.

Overall, Sanofi appears undervalued on its P/E multiple, with the market pricing its earnings at a lower level than both peers and the modelled fair ratio.

See what the numbers say about this price — find out in our valuation breakdown.

The Sanofi Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Sanofi pick up where this valuation puzzle leaves off by spelling out which assumptions about Sanofi's future growth, margins and earnings would need to hold for the stock to be worth materially more or less than today's price, based on scenarios that live on the company's Community page. Each narrative links a specific mix of potential catalysts and risks to an implied fair value, so you can see which story about Sanofi's future seems to be unfolding over time.

One of the top community narratives on Sanofi: 21% undervalued

"Continued investment in innovative products, strategic acquisitions, and portfolio streamlining is positioning Sanofi for long-term growth in high-value therapeutic areas..."

Read one of the top narratives on Sanofi

Do you think there's more to the story for Sanofi? Head over to our Community to see what others are saying!

The Bottom Line

Sanofi screens as undervalued on its current P/E, which suggests the market is not paying a high price for its existing earnings profile. For you, the real question is whether that discount reflects lingering concern about execution across the pipeline and key products or a mispricing that could close if sentiment improves. The crux of the bull versus bear debate is whether Sanofi can translate its product and R&D progress into durable earnings that eventually justify a higher multiple, rather than the discount persisting as a warning of a potential value trap.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com